TARGETING CANCER’S MOST commonly mutated pathway


There are approximately 5.5 million new cases of cancer per year with RAS/MAPK pathway alterations, over 90% of which have limited or no treatment options. While the RAS/MAPK pathway has been well characterized and validated based on the development and approval of multiple compounds targeting discrete signaling nodes in the pathway, most of these compounds face resistance and tolerability challenges, highlighting the need for new approaches to target this important signaling cascade.

Implicated in approximately one-third of solid tumors, including:

  • Glioblastoma multiforme (GBM)
  • Head & neck squamous cell carcinoma (HNSCC)
  • Non-small cell lung cancer (NSCLC)
  • Colorectal cancer (CRC)
  • Melanoma
  • Pancreatic ductal adenocarcinoma (PDAC)

Implicated in liquid tumors,

  • Acute myelogenous leukemia (AML)

Our mission will involve delivering new therapies to patients in markets where there are limited or no approved therapies, which are referred to as “blue oceans” (Blue Ocean Strategy by Chan Kim & Renée Mauborgne), as well as markets where there are already approved product offerings, or “red oceans.” Of the approximately 5.5 million new patients diagnosed globally per year with cancers driven by RAS/MAPK pathway alterations, over 90% (approximately 5 million patients) are in blue oceans with limited or no treatment options.

New cases estimated
worldwide per annum (thousands; numbers may not
add up due to rounding)

RAS/MAPK Pathway Alterations GBM HNSCC NSCLC CRC Melanoma PDAC Other solid tumors AML US EU ROW Global
EGFR*/FLT3 125 513 184 338 61 82 222 917 1,220
NF1 25 58 98 35 33 1.9 434 3.2 75 159 453 687
KRAS G12C 2.8 240 57 5.0 45 0.1 36 82 232 350
Other KRAS 0.5 14.1 252 703 1.6 420 527 4.7 179 470 1.273 1.922
NRAS 0.5 8.4 11.7 72 71 1.0 116 13.8 42 82 170 295
HRAS 0.2 45 7.8 0.4 3.0 0.2 57 11 24 80 114
BRAF V600E/K 2 1.9 23 180 93 1.4 158 0.4 63 127 271 461
Other BRAF 0.5 4.7 33 24 9.7 0.8 87 0.2 18 39 103 160
MEK 0.2 1.9 11.7 8.8 4.6 0.2 22 5 11 33 50
Co-occurring activating
MAPK pathway alterations**
1.4 10.3 62 59 37 7.1 84 3.0 33 169 162 264
US 12 29 93 114 77 51 153 11 542
EU 34 76 194 398 116 124 324 18 1,285
Rest of World 109 555 635 964 60 264 1.053 57 3,696
Global 155 660 923 1,476 253 438 1,530 86 5,522
Blue ocean opportunties Red ocean opportunties
*   Post-Osimertinib resistant population shown for EGFRm NSCLC except for SCLC transformation
** Co-occurring activating MAPK pathway alterations exclude EGFR overexpression Source: SEER database (2020), ECIS database (2020), GLOBOCAN database (2020), The AACR Project GENIE Consortium version 8.1 (2020), TCGA Research Network:, Tyner JW et al. (2018) PMID: 30333627, Brenner CW et al (2013) PMID: 24120142, Chen J et al. (2020) PMID: 32015526, and Ostrom QT, et al. (2020) PMID: 33123732

Our comprehensive clinical development plan enables us to address significant portions of patient populations across tissue-specific and tissue-agnostic indications.

INDICATION populations
HNSCC HPV negative
Melanoma RASm, BRAFm
GBM EGFR altered
Pan tumor (tissue agnostic) Remainder of ~5.5m patients with RAS/MAPK alterations

MAPKlamp & More

Using innovative science and working with world-class collaborators, we are taking a holistic, modality-agnostic approach to effectively shut down the RAS/MAPK pathway. We are not just targeting individual signaling nodes. Rather, we seek to turn off multiple nodes and cooperative mechanisms along the pathway in parallel. To accomplish this, we are pursuing three therapeutic strategies that work together to comprehensively, and perhaps synergistically, shut down the RAS/MAPK pathway.

Our 3 therapeutic strategies

To learn more about our three therapeutic strategies and how they can help us overcome RAS/MAPK pathway-driven cancers, click on the numbers below.

Target upstream and downstream MAPK nodes

with single agents and
clamp oncogenic drivers (MAPKlamp) with combinations

Our proprietary MAPKlamp strategy targets upstream and downstream nodes of the RAS/MAPK pathway, initially SHP2 (ERAS-601) and ERK (ERAS-007), respectively, to shut down, or clamp, the signaling of various oncogenic drivers, such as RAS, RAF, and MEK alterations, trapped in between these nodes. With our MAPKlamp approach, we hope to induce tumor regression in RAS/MAPK pathway-driven cancers, while also blocking their main escape routes. We are also discovering and developing single agent and combination approaches to target other upstream nodes that impact the RAS/MAPK pathway such as EGFR (ERAS-801), a receptor tyrosine kinase that represents a key escape route for MAPK signaling, and SOS1 (ERAS-9), a guanine nucleotide exchange factor that enables RAS to cycle from the inactive GDP state to the active GTP state.

Target RAS directly

with single agents and combinations with
upstream, downstream,
and escape route targeted

Targeting RAS directly with single agents and combinations. We are discovering and developing molecules with the potential to inhibit RAS in its inactive GDP state as well as its more prevalent active GTP state. Utilizing our in-house discovery efforts employing structure-based drug design, we are developing a central nervous system (CNS)-penetrant inhibitor of KRAS G12C (ERAS-1), which is the only RAS isoform and mutation that is more commonly present in the inactive RAS-GDP state. We are also developing proprietary compounds against KRAS G12D (ERAS-4), which is more commonly found in the active RAS-GTP state and is the most prevalent KRAS mutation. Our approach to targeting other RAS isoforms and mutations also found more commonly in the RAS-GTP state is based on the foundational discoveries of one of our co-founders, Dr. Kevan Shokat, a world-renowned pioneer of novel therapeutic approaches targeting key cancer signaling pathways such as the RAS/MAPK pathway.

Target escape routes

enabled by other proteins
or pathways to further
disrupt RAS/MAPK
pathway signaling

Targeting escape routes enabled by other proteins or pathways to further disrupt RAS/MAPK pathway signaling. RAS-driven cancers utilize cooperative mechanisms to develop resistance. As an example, RAS-driven cancers can become dependent on autophagy, which becomes constitutively active and represents a potential escape route for metabolically active tumors such as pancreatic ductal adenocarcinoma. By targeting ULK (ERAS-5), a key regulator of autophagy, in combination with our RAS targeting agents, we aim to shut down this potential escape route for RAS-driven cancers. We also are actively pursuing various ways to further disrupt RAS/MAPK pathway signaling by degrading key proteins. Finally, MYC (ERAS-11) is a transcription factor and oncogene that is overexpressed in the majority of cancers and a key enabler of RAS/MAPK pathway signaling at the transcriptional level.

Our strategic focus on the RAS/MAPK pathway allows us to comprehensively target every critical node in the pathway that could drive signaling. In fact, we currently have programs targeting each of the nodes colored in purple below.

Publications & Presentations